Diabetes and Bone

Heilmeier, Ursula; Patsch, Janina

doi:10.1055/s-0036-1592366

Cited by 15 publications

(11 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These effects influence bone metabolism and then cause bone loss and destruction of bone ultrastructure. 25 In recent years, studies have shown that insulin directly affects bone cells, 14 but the relationship between insulin resistance and osteoporosis is still unclear. Bilic-Curcic et al 26 proposed that abdominal obesity and hyperinsulinemia played a protective role in postmenopausal women with T2DM, leading to an increase in the total femoral bone density.…”

Section: Discussionmentioning

confidence: 99%

Association Analysis of Insulin Resistance and Osteoporosis Risk in Chinese Patients with T2DM

Wang¹,

Jiang²,

Shao³

2021

TCRM

View full text Add to dashboard Cite

Background: To explore the relationship between insulin resistance and osteoporosis risk in Chinese patients with type 2 diabetes mellitus (T2DM). Methods: A total of 234 T2DM patients were retrospectively analyzed, and their lumbar bone mineral density (BMD) and insulin resistance using C-peptide-based homeostasis model of insulin resistance [HOMA-IR (CP)] were assessed. Univariate and multivariable logistic regression methods were used to evaluate the association between HOMA-IR (CP) and osteoporosis, and subgroup analysis was performed on female and male patients. Results: After fully adjusting the covariates, the association between HOMA-IR (CP) and osteoporosis was only significant in female patients (P = 0.022); the interaction effect with gender was significant (P for interaction <0.05). Curve fitting showed that the relationship between HOMA-IR (CP) and osteoporosis in women was nonlinear. When HOMA-IR (CP) is <4.00, its effect on osteoporosis was not significant (P = 0.474); when HOMA-IR (CP) is >4.00, the risk of osteoporosis increased significantly, with OR = 26.88 (95% CI: 2.75-262.69, P = 0.005). The relationship between insulin resistance and osteoporosis risk in T2DM patients is significantly affected by gender. Conclusion:The higher the degree of insulin resistance in female patients, the greater the risk of osteoporosis, but the two are not linearly associated.

show abstract

Section: Discussionmentioning

confidence: 99%

Association Analysis of Insulin Resistance and Osteoporosis Risk in Chinese Patients with T2DM

Wang¹,

Jiang²,

Shao³

2021

TCRM

View full text Add to dashboard Cite

show abstract

“…Diabetes is associated with an increased fracture risk also after biochemical control of acromegaly (125). To date the pathophysiological evidence linking insulin resistance with bone diseases is scarce, but cohort studies show impaired bone turnover, increased incidence of osteoporosis and fracture risk in non-acromegalic patients with diabetes (126, 127). GH and IGF-1 increase bone turnover and acromegaly is associated with distinct alterations in bone compartments showing lower trabecular bone quantitative parameters, while cortical bone density seems better preserved and found decreased only in patients with vertebral fractures (128).…”

Section: Role Of Insulin-resistance In the Development Of Acromegaly-mentioning

confidence: 99%

Insulin Resistance in Patients With Acromegaly

et al. 2019

View full text Add to dashboard Cite

Acromegaly is characterized by chronic overproduction of growth hormone (GH) that leads to insulin resistance, glucose intolerance and, ultimately, diabetes. The GH-induced sustained stimulation of lipolysis plays a major role not only in the development of insulin resistance and prediabetes/diabetes, but also in the reduction of lipid accumulation, making acromegaly a unique case of severe insulin resistance in the presence of reduced body fat. In the present review, we elucidate the effects of GH hypersecretion on metabolic organs, describing the pathophysiology of impaired glucose tolerance in acromegaly, as well as the impact of acromegaly-specific therapies on glucose metabolism. In addition, we highlight the role of insulin resistance in the development of acromegaly-associated complications such as hypertension, cardiac disease, sleep apnea, polycystic ovaries, bone disease, and cancer. Taken together, insulin resistance is an important metabolic hallmark of acromegaly, which is strongly related to disease activity, the development of comorbidities, and might even impact the response to drugs used in the treatment of acromegaly.

show abstract

“…The animals were randomly divided into four groups (10 animals per group): [1] non-diabetic mice (non-DM), [2] T2DM mice treated with vehicle (0.2% CMC-Na) (T2DM), [3] T2DM mice treated with 3 mg/kg linagliptin (Lina 3), and [4] T2DM mice treated with 30 mg/kg linagliptin (Lina 30). The drug doses were selected based on a previous report (17) relevant to the effective doses of linagliptin with regard to glucose metabolism in obese mice.…”

Section: Methodsmentioning

confidence: 99%

“…Diabetes mellitus increases bone fragility by affecting bone metabolism, resulting in secondary osteoporosis, which increases the risk of fractures in patients (3)(4)(5)(6)(7). Furthermore, it has been revealed that several oral hypoglycemic agents affect bone metabolism (8).…”

Section: Introductionmentioning

confidence: 99%

Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice

Kanda

Furukawa

Izumo

et al. 2020

DD&T

View full text Add to dashboard Cite

Dipeptidyl peptidase-4 inhibitor, type 2 diabetes mellitus, bone fragility Recently, it has been suggested that glucose-dependent insulinotropic polypeptide (GIP) and glucagonlike peptide 1 (GLP-1), which play important roles in the homeostasis of glucose metabolism, could be involved in the regulation of bone metabolism. Inhibitors of dipeptidyl peptidase 4 (DPP-4), an enzyme that degrades GIP and GLP-1, are widely used clinically as a therapeutic agent for diabetes. However, the effects of DPP-4 inhibitors on bone metabolism remain unclear. In this study, we investigated the effects of linagliptin, a DPP-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus (T2DM). Non-diabetic mice were used as controls, and T2DM mice were administered linagliptin orally on a daily basis for 12 weeks. In T2DM mice, decreased bone mineral density was observed in the lower limb bones along with low serum osteocalcin levels and high serum tartrate-resistant acid phosphatase-5b (TRAP) levels. In contrast, the decreased serum osteocalcin levels and increased serum TRAP levels observed in T2DM mice were significantly suppressed after the administration of linagliptin 30 mg/kg. Bone histomorphometric analysis revealed a reduced osteoid volume and osteoblast surface with an increase in the eroded surface and number of osteoclasts in T2DM mice. This decreased bone formation and increased bone resorption observed in the T2DM mice were suppressed and trabecular bone volume increased following the administration of 30 mg/kg linagliptin. Collectively, these findings suggest that linagliptin may improve the microstructure of trabecular bone by inhibiting both a decrease in bone formation and an increase in bone resorption induced by T2DM.

show abstract

Diabetes and Bone

Cited by 15 publications

References 57 publications

Association Analysis of Insulin Resistance and Osteoporosis Risk in Chinese Patients with T2DM

Association Analysis of Insulin Resistance and Osteoporosis Risk in Chinese Patients with T2DM

Insulin Resistance in Patients With Acromegaly

Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice

Contact Info

Product

Resources

About